IHS Chemical Week

Regions :: Western Europe :: Belgium

Abbott Secures Conditional EU Approval for Solvay Drugs Acquisition

10:43 AM MST | February 12, 2010 | Natasha Alperowicz

Abbott Laboratories has secured conditional EU approval for the acquisition of the drug unit of Solvay. Abbott will need to divest the cystic fibrosis testing business of Solvay pharma's subsidiary Innogenetics in Europe, as part of the approval. The European Commission said it had concerns that the combined market share in cystic fibrosis testing could harm competition. Abbott announced last September that it had agreed to buy Solvay's pharma business for €4.5 billion ($6.2 billion). The move will transform Solvay from a chemical-pharmaceutical hybrid...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa